These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27716818)

  • 41. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
    Kroeze S; Ondoa P; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; de Pundert ME; Sigaloff KCE; Reiss P; Wit FWNM; Rinke de Wit TF; Hamers RL
    AIDS; 2018 May; 32(8):1043-1051. PubMed ID: 29547445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adherence to On-Time ART Drug Pick-Up and Its Association with CD4 Changes and Clinical Outcomes Amongst HIV Infected Adults on First-Line Antiretroviral Therapy in Nigerian Hospitals.
    Anoje C; Agu KA; Oladele EA; Badru T; Adedokun O; Oqua D; Khamofu H; Adebayo O; Torpey K; Chabikuli ON
    AIDS Behav; 2017 Feb; 21(2):386-392. PubMed ID: 27388161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.
    D'Amico R; Yang Y; Mildvan D; Evans SR; Schnizlein-Bick CT; Hafner R; Webb N; Basar M; Zackin R; Jacobson MA
    J Clin Immunol; 2005 Mar; 25(2):106-15. PubMed ID: 15821887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
    Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
    Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer.
    De La Mata NL; Ly PS; Ng OT; Nguyen KV; Merati TP; Pham TT; Lee MP; Choi JY; Sohn AH; Law MG; Kumarasamy N
    Int J STD AIDS; 2017 Nov; 28(13):1282-1291. PubMed ID: 28632481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors associated with CD4 + cell count recovery among males and females with advanced HIV disease.
    Kouamou V; Gundidza P; Ndhlovu CE; Makadzange AT;
    AIDS; 2023 Dec; 37(15):2311-2318. PubMed ID: 37598355
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
    Gianotti N; Lorenzini P; Cozzi-Lepri A; De Luca A; Madeddu G; Sighinolfi L; Pinnetti C; Santoro C; Meraviglia P; Mussini C; Antinori A; d'Arminio Monforte A;
    J Antimicrob Chemother; 2019 Sep; 74(9):2732-2741. PubMed ID: 31173639
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD4+ cell count recovery following initiation of HIV antiretroviral therapy in older childhood and adolescence.
    Simms V; Rylance S; Bandason T; Dauya E; McHugh G; Munyati S; Mujuru H; Rowland-Jones SL; Weiss HA; Ferrand RA
    AIDS; 2018 Sep; 32(14):1977-1982. PubMed ID: 29927784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effective linkage from point of HIV testing to care and treatment in Tanga region, Tanzania.
    Kayabu DE; Ngocho JS; Mmbaga BT
    PLoS One; 2018; 13(8):e0201644. PubMed ID: 30114244
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial.
    Maggiolo F; Ripamonti D; Gregis G; Quinzan G; Callegaro A; Suter F
    AIDS; 2004 Feb; 18(3):439-46. PubMed ID: 15090796
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Weight change at 1 mo of antiretroviral therapy and its association with subsequent mortality, morbidity, and CD4 T cell reconstitution in a Tanzanian HIV-infected adult cohort.
    Sudfeld CR; Isanaka S; Mugusi FM; Aboud S; Wang M; Chalamilla GE; Giovannucci EL; Fawzi WW
    Am J Clin Nutr; 2013 Jun; 97(6):1278-87. PubMed ID: 23636235
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis.
    Gezie LD
    BMC Res Notes; 2016 Jul; 9():377. PubMed ID: 27475982
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of point-of-care CD4 cell count results on linkage to care and antiretroviral initiation during a home-based HIV testing campaign: a non-blinded, cluster-randomised trial.
    Desai MA; Okal DO; Rose CE; Ndivo R; Oyaro B; Otieno FO; Williams T; Chen RT; Zeh C; Samandari T
    Lancet HIV; 2017 Sep; 4(9):e393-e401. PubMed ID: 28579225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania.
    Hawkins C; Christian B; Ye J; Nagu T; Aris E; Chalamilla G; Spiegelman D; Mugusi F; Mehta S; Fawzi W
    AIDS; 2013 Mar; 27(6):919-927. PubMed ID: 23196935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
    Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA
    AIDS Res Hum Retroviruses; 2009 Jun; 25(6):756-76. PubMed ID: 19500017
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
    Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
    Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa.
    Boyer S; Iwuji C; Gosset A; Protopopescu C; Okesola N; Plazy M; Spire B; Orne-Gliemann J; McGrath N; Pillay D; Dabis F; Larmarange J;
    AIDS Care; 2016; 28 Suppl 3(Suppl 3):39-51. PubMed ID: 27421051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.